Activation of RXR/PPARγ underlies neuroprotection by bexarotene in ischemic stroke

Pharmacological Research

Volumn 102, Issue , 2015, Pages 298-307

  Certo, Michelangelo ^a   Endo, Yasuyuki ^b   Ohta, Kiminori ^b   Sakurada, Shinobu ^b   Bagetta, Giacinto ^a   Amantea, Diana ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Bexarotene; Drug repurposing; Immunomodulation; Ischemic stroke; Neutrophils; Retinoid X receptors

Indexed keywords

BEXAROTENE; BISPHENOL A DIGLYCIDYL ETHER; BR 1211; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; RETINOID X RECEPTOR; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; TETRALIN DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW CELL; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BRAIN SLICE; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMIDITY; IMMUNOFLUORESCENCE; IMMUNOMODULATION; IMMUNOREGULATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NEUTROPHIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; METABOLISM; STROKE;

ANIMALS; BRAIN ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; PPAR GAMMA; RETINOID X RECEPTORS; STROKE; TETRAHYDRONAPHTHALENES;

EID: 84947050189     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.10.009     Document Type: Article

References (98)

1. D. Mozaffarian, E.J. Benjamin, A.S. Go, D.K. Arnett, M.J. Blaha, M. Cushman, and et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2015 update: a report from the American Heart Association Circulation 131 2015 434 441
2. S. Mangiafico, and A. Consoli Genomics for the advancement of clinical translation in stroke G. Micieli, D. Amantea, Rational Basis for Clinical Translation in Stroke Therapy 2014 CRC press Boca Raton, FL 24 36
3. O.A. Berkhemer, P.S. Fransen, D. Beumer, L.A. van den Berg, H.F. Lingsma, A.J. Yoo, and et al. The MR CLEAN investigators. A randomized trial of intraarterial treatment for acute ischemic stroke N. Engl. J. Med. 372 2015 11 20
4. W. Hacke Interventional thrombectomy for major stroke - a step in the right direction N. Engl. J. Med. 372 2015 76 77
5. H.M. Hussein, A.L. Georgiadis, G. Vazquez, J.T. Miley, M.Z. Memon, Y.M. Mohammad, G.A. Christoforidis, and et al. Occurrence and predictors of futile recanalization following endovascular treatment among patients with acute ischemic stroke: a multicenter study AJNR Am. J. Neuroradiol. 31 2010 454 458
6. P.M. Meyers, H.C. Schumacher, E.S. Connolly, E.J. Heyer, W.A. Gray, and R.T. Higashida Current status of endovascular stroke treatment Circulation 123 2011 2591 2601
7. A.T. Rai, Y. Jhadhav, J. Domico, and G.R. Hobbs Procedural predictors of outcome in patients undergoing endovascular therapy for acute ischemic stroke Cardiovasc. Interv. Radiol. 35 2012 1332 1339
8. D. Amantea, G. Micieli, C. Tassorelli, M.I. Cuartero, I. Ballesteros, M. Certo, and et al. Rational modulation of the innate immune system for neuroprotection in ischemic stroke Front. Neurosci. 9 2015 147
9. Y. Tang, H. Xu, X. Du, L. Lit, W. Walker, A. Lu, and et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study J. Cereb. Blood Flow Metab. 26 2006 1089 1102
10. T.L. Barr, Y. Conley, J. Ding, A. Dillman, S. Warach, A. Singleton, and M. Matarin Genomic biomarkers and cellular pathways of ischemic stroke by RNA gene expression profiling Neurology 75 2010 1009 1014
11. S.D. Brooks, R. Van Gilder, J.C. Frisbee, and T.L. Barr Genomics for the advancement of clinical translation in stroke G. Micieli, D. Amantea, Rational Basis for Clinical Translation in Stroke Therapy 2014 CRC press Boca Raton, FL 123 136
12. M.A. Michell-Robinson, H. Touil, L.M. Healy, D.R. Owen, B.A. Durafourt, A. Bar-Or, and et al. Roles of microglia in brain development, tissue maintenance and repair Brain 138 2015 1138 1159
13. Y. Xu, L. Qian, G. Zong, K. Ma, X. Zhu, H. Zhang, and et al. Class A scavenger receptor promotes cerebral ischemic injury by pivoting microglia/macrophage polarization Neuroscience 218 2012 35 48
14. S. Fumagalli, C. Perego, F. Ortolano, and M.G. De Simoni CX3CR1 deficiency induces an early protective inflammatory environment in ischemic mice Glia 61 2013 827 842
15. M.I. Cuartero, I. Ballesteros, A. Moraga, F. Nombela, J. Vivancos, J.A. Hamilton, and et al. N2 neutrophils, novel players in brain inflammation after stroke: modulation by the PPARγ agonist rosiglitazone Stroke 44 2013 3498 3508
16. L. Nagy, A. Szanto, I. Szatmari, and L. Széles Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response Physiol. Rev. 92 2012 739 789
17. M. Kiss, Z. Czimmerer, and L. Nagy The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: from physiology to pathology J. Allergy Clin. Immunol. 132 2013 264 286
18. S.Y. Na, B.Y. Kang, S.W. Chung, S.J. Han, X. Ma, G. Trinchieri, and et al. Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB J. Biol. Chem. 274 1999 7674 7680
19. V. Núñez, D. Alameda, D. Rico, R. Mota, P. Gonzalo, M. Cedenilla, and et al. Retinoid X receptor alpha controls innate inflammatory responses through the up-regulation of chemokine expression Proc. Natl. Acad. Sci. U. S. A. 107 2010 10626 10631
20. C.K. Glass, and K. Saijo Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells Nat. Rev. Immunol. 10 2010 365 376
21. C. Kilkenny, W.J. Browne, I.C. Cuthill, M. Emerson, and D.G. Altman Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research PLoS Biol. 8 6 2010 e1000412
22. K. Ohta, T. Iijima, E. Kawachi, H. Kagechika, and Y. Endo Novel retinoid X receptor (RXR) antagonists having a dicarba-closo-dodecaborane as a hydrophobic moiety Bioorg. Med. Chem. Lett. 14 2004 5913 5918
23. M. Wietrzych-Schindler, M. Szyszka-Niagolov, K. Ohta, Y. Endo, E. Pérez, A.R. de Lera, and et al. Retinoid x receptor gamma is implicated in docosahexaenoic acid modulation of despair behaviors and working memory in mice Biol. Psychiatry 69 2011 788 794
24. H.M. Wright, C.B. Clish, T. Mikami, S. Hauser, K. Yanagi, R. Hiramatsu, and et al. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation J. Biol. Chem. 275 2000 1873 1877
25. A. Yamamoto, H. Kakuta, H. Miyachi, and Y. Sugimoto Involvement of the retinoid X receptor ligand in the anti-inflammatory effect induced by peroxisome proliferator-activated receptor γ agonist in vivo PPAR Res. 2011 2011 840194
26. G. Paxinos, and K.N.J. Franklin The Mouse Brain in Stereotaxic Coordinates Fourth edition 2012 Academic press San Diego, USA
27. M. Armogida, A. Spalloni, D. Amantea, M. Nutini, F. Petrelli, P. Longone, and et al. The protective role of catalase against cerebral ischemia in vitro and in vivo Int. J. Immunopathol. Pharmacol. 24 2011 735 747
28. E.Z. Longa, P.R. Weinstein, S. Carlson, and R. Cummins Reversible middle cerebral artery occlusion without craniotomy in rats Stroke 20 1989 84 91
29. A. Manaenko, H. Chen, J. Kammer, J.H. Zhang, and J. Tang Comparison Evans Blue injection routes: intravenous versus intraperitoneal, for measurement of blood-brain barrier in a mice hemorrhage model J. Neurosci. Methods 195 2011 206 210
30. T.J. Fleming, M.L. Fleming, and T.R. Malek Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow: RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family J. Immunol. 151 1993 2399 2408
31. M. Nahrendorf, M.J. Pittet, and F.K. Swirski Monocytes protagonists of infarct inflammation and repair after myocardial infarction Circulation 121 2010 2437 2445
32. M. Rosas, B. Thomas, M. Stacey, S. Gordon, and P.R. Taylor The myeloid 7/4-antigen defines recently generated inflammatory macrophages and is synonymous with Ly-6B J. Leukoc. Biol. 88 2010 169 180
33. S. Gordon, and F.O. Martinez Alternative activation of macrophages: mechanism and functions Immunity 32 2010 593 604
34. K. Prass, C. Meisel, C. Höflich, J. Braun, E. Halle, T. Wolf, and et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation J. Exp. Med. 198 5 2003 725 736
35. A. Liesz, S. Hagmann, C. Zschoche, J. Adamek, W. Zhou, L. Sun, and et al. The spectrum of systemic immune alterations after murine focal ischemia: immunodepression versus immunomodulation Stroke 40 2009 2849 2858
36. R. Jin, X. Zhu, L. Liu, A. Nanda, D.N. Granger, and G. Li Simvastatin attenuates stroke-induced splenic atrophy and lung susceptibility to spontaneous bacterial infection in mice Stroke 44 2013 1135 1143
37. P.E. Cramer, J.R. Cirrito, D.W. Wesson, C.Y. Lee, J.C. Karlo, A.E. Zinn, and et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models Science 335 2012 1503 1506
38. G.E. Landreth, P.E. Cramer, M.M. Lakner, J.R. Cirrito, D.W. Wesson, K.R. Brunden, and D.A. Wilson Response to comments on ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models Science 340 2013 924
39. B.H. Rotstein, J.M. Hooker, J. Woo, T.L. Collier, T.J. Brady, S.H. Liang, and N. Vasdev Synthesis of [(11)C] bexarotene by Cu-mediated [(11)C] carbon dioxide fixation and preliminary PET imaging ACS Med. Chem. Lett. 5 2014 668 672
40. J.E. Henney From the food and drug administration JAMA 283 2000 1131
41. M. Duvic, A.G. Martin, Y. Kim, E. Olsen, G.S. Wood, C.A. Crowley, and R.C. Yocum Worldwide bexarotene study group: phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma Arch. Dermatol. 137 2001 581 593
42. L.T. Farol, and K.B. Hymes Bexarotene a clinical review Expert Rev. Anticancer Ther. 4 2004 180 188
43. R.M. Evans, and D.J. Mangeldorf Nuclear receptors, RXR and the big bang Cell 157 2014 255 266
44. R. Kurokawa, V.C. Yu, A. Näär, S. Kyakumoto, Z. Han, S. Silverman, and et al. Differential orientations of the DNA-binding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers Genes Dev. 7 7B 1993 1423 1435
45. B.M. Forman, K. Umesono, J. Chen, and R.M. Evans Unique response pathways are established by allosteric interactions among nuclear hormone receptors Cell 81 1995 541 550
46. A.I. Shulman, and D.J. Mangelsdorf Retinoid x receptor heterodimers in the metabolic syndrome N. Engl. J. Med. 353 2005 604 615
47. M.F. Boehm, L. Zhang, B.A. Badea, S.K. White, D.E. Mais, E. Berger, and et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids J. Med. Chem. 37 1994 2930 2941
48. R. Mukherjee, P.J. Davies, D.L. Crombie, E.D. Bischoff, R.M. Cesario, L. Jow, and et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists Nature 386 6623 1997 407 410
49. P.T. Vedell, Y. Lu, C.J. Grubbs, Y. Yin, H. Jiang, K.I. Bland, and et al. Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and targretin (Bexarotene) Mol. Pharmacol. 83 2013 698 708
50. R. Mukherjee, J. Strasser, L. Jow, P. Hoener, J.R. Paterniti Jr., and R.A. Heyman RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo Arterioscler. Thromb. Vasc. Biol. 18 1998 272 276
51. M.R. Robciuc, H.A. Skrobuk Pet al Koistinen, M. Jauhiainen, and C. Ehnholm Angiopoietin-like 4 mediates PPAR delta effect on lipoprotein lipase-dependent fatty acid uptake but not on beta-oxidation in myotubes PLoS One 7 2012 e46212
52. W.C. Yen, R.Y. Prudente, M.R. Corpuz, A. Negro-Vilar, and W.W. Lamph A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours Br. J. Cancer 94 2006 654 660
53. J.P. Klopper, V. Sharma, A. Berenz, W.R. Hays, M. Loi, U. Pugazhenthi, and et al. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression Mol. Cancer 8 2009 16
54. M.J. Sanz, F. Albertos, E. Otero, M. Juez, E.J. Morcillo, L. Piqueras, and X. Retinoid Receptor agonists impair arterial mononuclear cell recruitment through peroxisome proliferator-activated receptor-γ activation J. Immunol. 189 2012 411 424
55. A.M. Lehman, J.R. Montford, H. Horita, A.C. Ostriker, M.C. Weiser-Evans, R.A. Nemenoff, and S.B. Furgeson Activation of the retinoid X receptor modulates angiotensin II-induced smooth muscle gene expression and inflammation in vascular smooth muscle cells Mol. Pharmacol. 86 2014 570 579
56. M. Shimizu, and H. Moriwaki Synergistic effects of PPARgamma ligands and retinoids in cancer treatment PPAR Res. 2008 2008 181047
57. L.S. Chan, and R.A. Wells Cross-talk between PPARs and the partners of RXR: a molecular perspective PPAR Res. 2009 2009 925309
58. Y. Wu, and S.W. Guo Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells Fertil. Steril. 91 Suppl. (5) 2009 2142 2147
59. T. Shimazu, I. Inoue, N. Araki, Y. Asano, M. Sawada, D. Furuya, and et al. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia Stroke 36 2005 353 359
60. S. Sundararajan, J.L. Gamboa, N.A. Victor, E.W. Wanderi, W.D. Lust, and G.E. Landreth Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia Neuroscience 130 2005 685 696
61. Y. Luo, W. Yin, A.P. Signore, F. Zhang, Z. Hong, S. Wang, and et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone J. Neurochem. 97 2006 435 448
62. M.P. Pereira, O. Hurtado, A. Cárdenas, L. Boscá, J. Castillo, A. Dávalos, and et al. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms J. Cereb. Blood Flow Metab. 26 2 2006 218 229
63. Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats FASEB J. 20 2006 1162 1175
64. I. Ballesteros, M.I. Cuartero, J.M. Pradillo, J. de la Parra, A. Pérez-Ruiz, A. Corbí, and et al. Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARγ and 5-LO-dependent pathways J. Leukoc. Biol. 95 2014 587 598
65. T. Ouk, C. Potey, S. Gautier, M. Bastide, D. Deplanque, B. Staels, and et al. PPARs: a potential target for a disease-modifying strategy in stroke Curr. Drug Targets 14 7 2013 752 767
66. K. Tureyen, R. Kapadia, K.K. Bowen, I. Satriotomo, J. Liang, D.L. Feinstein, and R. Vemuganti Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents J. Neurochem. 101 1 2007 41 56
67. A. Mantovani, M.A. Cassatella, C. Costantini, and S. Jaillon Neutrophils in the activation and regulation of innate and adaptive immunity Nat. Rev. Immunol. 11 8 2011 519 531
68. R.A. Frieler, H. Meng, S.Z. Duan, S. Berger, G. Schütz, Y. He, and et al. Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia Stroke 42 2011 179 185
69. J. Pan, J.L. Jin, H.M. Ge, K.L. Yin, X. Chen, L.J. Han, and et al. Malibatol A regulates microglia M1/M2 polarization in experimental stroke in a PPARγ-dependent manner J. Neuroinflamm. 12 1 2015 51
70. K. Mehta, T. McQueen, S. Tucker, R. Pandita, and B.B. Aggarwal Inhibition by all-transretinoic acid of tumor necrosis factor and nitric oxide production by peritoneal macrophages J. Leukoc. Biol. 55 1994 336 342
71. C. Marathe, M.N. Bradley, C. Hong, F. Lopez, C.M. Ruiz de Galarreta, P. Tontonoz, and A. Castrillo The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages J. Biol. Chem. 281 2006 32197 32206
72. X. Wang, C. Allen, and M. Ballow Retinoic acid enhances the production of IL-10 while reducing the synthesis of IL-12 and TNF-alpha from LPS-stimulated monocytes/macrophages J. Clin. Immunol. 27 2007 193 200
73. J.I. Odegaard, R.R. Ricardo-Gonzalez, M.H. Goforth, C.R. Morel, V. Subramanian, L. Mukundan, and et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance Nature 447 2007 1116 1120
74. S. Taschner, C. Koesters, B. Platzer, A. Jörgl, W. Ellmeier, T. Benesch, and H. Strobl Down-regulation of RXRalpha expression is essential for neutrophil development from granulocyte/monocyte progenitors Blood 109 2007 971 979
75. U. Dirnagl, J. Klehmet, J.S. Braun, H. Harms, C. Meisel, T. Ziemssen, and et al. Stroke-induced immunodepression: experimental evidence and clinical relevance Stroke 38 Suppl. (2) 2007 770 773
76. V.H. Brait, T.V. Arumugam, G.R. Drummond, and C.G. Sobey Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia J. Cereb. Blood Flow Metab. 32 2012 598 611
77. Á. Chamorro, Á. Meisel, Á.M. Planas, X. Urra, D. van de Beek, and R. Veltkamp The immunology of acute stroke Nat. Rev. Neurol. 8 7 2012 401 410
78. H. Offner, S. Subramanian, S.M. Parker, C. Wang, M.E. Afentoulis, A. Lewis, and et al. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages J. Immunol. 176 2006 6523 6531
79. C.T. Ajmo Jr., D.O. Vernon, L. Collier, A.A. Hall, S. Garbuzova-Davis, A. Willing, and et al. The spleen contributes to stroke-induced neurodegeneration J. Neurosci. Res. 86 2008 2227 2234
80. Y. Bao, E. Kim, S. Bhosle, H. Mehta, and S. Cho A role for spleen monocytes in post-ischemic brain inflammation and injury J. Neuroinflamm. 7 2010 92
81. H.A. Seifert, A.A. Hall, C.B. Chapman, L.A. Collier, A.E. Willing, and K.R. Pennypacker A transient decrease in spleen size following stroke corresponds to splenocyte release into systemic circulation J. Neuroimmune Pharmacol. 7 2012 1017 1024
82. H.A. Seifert, C.C. Leonardo, A.A. Hall, D.D. Rowe, L.A. Collier, S.A. Benkovic, and et al. The spleen contributes to stroke induced neurodegeneration through interferon gamma signaling Metab. Brain Dis. 27 2012 131 141
83. E. Kim, J. Yang, C.D. Beltran, and S. Cho Role of spleen-derived monocytes/macrophages in acute ischemic brain injury J. Cereb. Blood Flow Metab. 34 2014 1411 1419
84. M. Vendrame, C. Gemma, K.R. Pennypacker, and et al. Cord blood rescues stroke-induced changes in splenocyte phenotype and function Exp. Neurol. 199 2006 191 200
85. W.F. Westendorp, P.J. Nederkoorn, J.D. Vermeij, M.G. Dijkgraaf, and D. van de Beek Post-stroke infection: a systematic review and meta-analysis BMC Neurol. 11 2011 110
86. S.J. Whittaker, J.R. Marsden, M. Spittle, and R. Russell Jones British Association of Dermatologists; U.K. Cutaneous Lymphoma Group. Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas Br. J. Dermatol. 149 2003 1095 1107
87. J.J. Scarisbrick, S. Morris, R. Azurdia, T. Illidge, E. Parry, R. Graham-Brown, and et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma Br. J. Dermatol. 168 2013 192 200
88. C. Bachmeier, D. Beaulieu-Abdelahad, F. Crawford, M. Mullan, and D. Paris Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier J. Mol. Neurosci. 49 2013 270 276
89. N.F. Fitz, A.A. Cronican, I. Lefterov, and R. Koldamova Comment on ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models Science 340 2013 924
90. A.R. Price, G. Xu, Z.B. Siemienski, L.A. Smithson, D.R. Borchelt, T.E. Golde, and K.M. Felsenstein Comment on ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models Science 340 6135 2013 924
91. I. Tesseur, A.C. Lo, A. Roberfroid, S. Dietvorst, B. Van Broeck, M. Borgers, and et al. Comment on ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models Science 340 2013
92. K. Veeraraghavalu, C. Zhang, S. Miller, J.K. Hefendehl, T.W. Rajapaksha, J. Ulrich, and et al. Comment on ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models Science 340 2013 924
93. S. Friling, M. Bergsland, and S. Kjellander Activation of retinoid X receptor increases dopamine cell survival in models for Parkinson's disease BMC Neurosci. 10 2009 146
94. Wallén-Mackenzie, A. Mata de Urquiza, S. Petersson, F.J. Rodriguez, S. Friling, J. Wagner, and et al. Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells Genes Dev. 17 2003 3036 3047
95. Y. Shinozaki, Y. Sato, S. Koizumi, Y. Ohno, T. Nagao, and K. Inoue Retinoic acids acting through retinoid receptors protect hippocampal neurons from oxygen-glucose deprivation-mediated cell death by inhibition of c-jun-N-terminal kinase and p38 mitogen-activated protein kinase Neuroscience 147 2007 153 163
96. M.J. Keiser, V. Setola, J.J. Irwin, C. Laggner, A.I. Abbas, S.J. Hufeisen, and et al. Predicting new molecular targets for known drugs Nature 462 2009 175 181
97. S.C. Fagan Drug repurposing for drug development in stroke Pharmacotherapy 30 Pt 2 (7) 2010 51S 54S
98. D. Amantea, M. Certo, and G. Bagetta Drug repurposing and beyond: the fundamental role of pharmacology Funct. Neurol. 13 2015 85 87